{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+%28HCV%29&page=11", "query": { "condition": "Hepatitis C Virus (HCV)", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 920, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+%28HCV%29&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+%28HCV%29&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T20:16:39.597Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01180790", "title": "Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "ACH-0141625 (Sovaprevir)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pegylated Interferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2010-09", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2023-08-30", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01180790" }, { "nct_id": "NCT00978497", "title": "Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "ANA598", "type": "DRUG" }, { "name": "Peginterferon", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 97, "start_date": "2009-09", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2017-03-31", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 20, "location_summary": "Anaheim, California • Los Angeles, California • San Clemente, California + 17 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Clemente", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00978497" }, { "nct_id": "NCT01921400", "title": "The Pathogenesis of Hepatitis C Virus Vertical Transmission", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C", "Infection Transmission, Maternal-Fetal" ], "interventions": [], "intervention_types": [], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 38, "start_date": "2013-01", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-04-09", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01921400" }, { "nct_id": "NCT01250366", "title": "Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HCV (Genotype 1)" ], "interventions": [ { "name": "INX-08189", "type": "DRUG" }, { "name": "Placebo matching with INX-08189", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 70, "start_date": "2010-10", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2012-07-12", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 3, "location_summary": "Los Angeles, California • Plymouth, Minnesota • San Antonio, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Plymouth", "state": "Minnesota" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01250366" }, { "nct_id": "NCT01827657", "title": "Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "GSK2336805", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 31, "start_date": "2013-05-28", "completion_date": "2014-03-20", "has_results": false, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 4, "location_summary": "Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Lakewood", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01827657" }, { "nct_id": "NCT00018031", "title": "Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "Peginterferon alfa-2b", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2001-06", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2014-10-01", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00018031" }, { "nct_id": "NCT02631772", "title": "LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Sofosbuvir/Ledipasvir x 12 weeks", "type": "DRUG" }, { "name": "Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-06-01", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631772" }, { "nct_id": "NCT04427202", "title": "Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV", "Hepatitis C", "Opioid-use Disorder", "Injection Drug Use" ], "interventions": [ { "name": "Referral to harm reduction services", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 306, "start_date": "2020-08-14", "completion_date": "2023-08-16", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 2, "location_summary": "Carbondale, Illinois • Murphysboro, Illinois", "locations": [ { "city": "Carbondale", "state": "Illinois" }, { "city": "Murphysboro", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04427202" }, { "nct_id": "NCT05376371", "title": "Criminal Justice Coordinated Transitional Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV", "Hepatitis C", "Substance Use Disorders" ], "interventions": [ { "name": "CJC-TraC", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2022-11-29", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 2, "location_summary": "Oregon, Wisconsin • Union Grove, Wisconsin", "locations": [ { "city": "Oregon", "state": "Wisconsin" }, { "city": "Union Grove", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05376371" }, { "nct_id": "NCT01194037", "title": "A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection", "Genotype 1" ], "interventions": [ { "name": "recombinant variant of interferon-alpha 2b", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HanAll BioPharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2011-06-23", "completion_date": "2011-11-28", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-10-14T20:16:39.597Z", "location_count": 6, "location_summary": "Los Angeles, California • National City, California • Miami, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194037" } ] }